Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 2,532.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
2,544.00 2,546.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,661.14 370.23 151.41 16.9 5,836
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 2,532.00 GBX

Hikma Pharmaceuticals (HIK) Latest News

More Hikma Pharmaceuticals News
Hikma Pharmaceuticals Investors    Hikma Pharmaceuticals Takeover Rumours

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
02/12/202013:31Hikma Pharmaceuticals1,119
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-12-02 17:30:452,532.001734,380.36O
2020-12-02 17:24:552,513.191844,624.26O
2020-12-02 17:13:222,546.042857,256.22O
2020-12-02 17:06:572,555.741594,063.63O
2020-12-02 17:06:162,547.462446,215.80O
View all Hikma Pharmaceuticals trades in real-time

Hikma Pharmaceuticals (HIK) Top Chat Posts

Hikma Pharmaceuticals Daily Update: Hikma Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 2,481p.
Hikma Pharmaceuticals Plc has a 4 week average price of 2,432p and a 12 week average price of 2,387p.
The 1 year high share price is 2,766p while the 1 year low share price is currently 1,596p.
There are currently 230,495,233 shares in issue and the average daily traded volume is 825,540 shares. The market capitalisation of Hikma Pharmaceuticals Plc is £5,836,139,299.56.
robertball: Indeed...I'm just trying to figure out price reaction...oh well...we trundle on
steeplejack: The price will recover.The FDA approval is later than hoped but in the bigger scheme of things that's hardly a serious setback and actually the company thought such an outcome was quite possible as indicated by its guidance.
robertball: It's a defensive share, albeit with a promising outlook...
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a Twin Petes Investing Podcast a few days ago and part of our discussion covers HIK. We also talked in depth about the current situation in the Markets and how we reckon things could play out. Anyway, if you use Apple or Audioboom you can find it under the 'Conkers Corner' Channel (you want TPI Podcast 22) and you can find it on Soundcloud at the link below. Ideal listening Lockdown listening !! Cheers, WD @wheeliedealer hTTps://
ali47fish: the link shows many companies but not hik
broadwood: Hikma Pharmaceuticals upgrades outlook amid 'strong' sales in H1 Just what the doctor ordered. - Hikma Pharmaceuticals raised its outlook for its injectables and generics businesses after reporting strong sales in the first half of the year thanks to the launch of new products. The company said it expected full-year Injectables revenue to be in the range of $870m to $900m and core operating margin to be in the range of 36% to 38%. Generics revenue for the full year was expected to be in the range of $690m to $720m, with core operating margin in the range of 16% to 18%. Branded revenue, meanwhile, was expected to be higher in the second half of the year and with revenue growth in constant currency to be in the mid-single digits. The upgraded outlook comes as the company saw profits jumped on the back of an increase in revenues. For the six months ended 30 June 2019, pre-tax profits rose to $226m from $141m a year earlier and revenue grew 8% to $1,047m, reflecting 'strong sales of our in-market products and new product launches,' the company said. The interim dividend was raised by 17% to 14 cents per share.
broadwood: Hikma Pharmaceuticals swung to a profit on Wednesday after it boosted injectables revenue, though it warned of lower sales in its generics business due to price cuts. For the 12 months to 31 December, the company reported a profit of $408m compared with a loss of $738m a year earlier and revenue increased 8% to $2.07bn. Its injectables business delivered revenue of $826m a for the year in line with previous guidance for revenues in a range of $825m to $850m. Going forward, the company expected global Injectables revenue to be in the range of $850m to $900m in 2019, with revenue growth from new product launches and good demand for our in-market portfolio more than offsetting continued price erosion and an easing in demand for products on shortage. Core operating margin for injectables was expected in the range of 35% to 38% in 2019. Full-year generics revenue rose 13% to $692m, in with expectations for revenues between $675m and $700m. Generics were expected to generate revenue between $650m to $700m in 2019. 'We expect Branded revenue to grow in the mid-single digits in constant currency in 2019 Looking beyond 2019, we expect to benefit from our continued investment in R&D across our businesses and we will look to fill pipeline gaps through business development,' the company said.
broadwood: Hikma Pharmaceuticals said it was raising group full year guidance after solid performances from its injectibles and generics divisions. The global injectables business had offset increased competition in the US through the “breadth and resilience of our growing portfolio, good demand for recent launches and our ability to leverage our scale and flexibility to respond to market shortages”, the company said in a trading statement. Injectables revenue was now expected to be in the range of $825m - $850m and core injectables operating margin to be between 39% and 40%. Generics revenue was upgraded to $675m - to $700m with core operating margin to be in the low teens. The generics business continued to perform ahead of expectations, despite a challenging US retail market, with continued price erosion. “We have made good progress with our cost reduction initiatives, including the consolidation of our manufacturing and distribution facilities, and this is supporting the strong improvement in the profitability of our generics business this year,” Hikma said. The company added that it had signed an agreement with Vectura to develop and commercialise their Open, Inhale, Close (OIC) dry product inhaler (DPI) platform, including generic versions of GSK's five Ellipta DPI products. "The generic respiratory market is a key area of focus for Hikma. This agreement leverages the investment we have made and the experience we are gaining through our generic Advair Diskus development programme," it said. Hikma will make an upfront payment of $15m to Vectura with $5m payable on transfer of the first product to Hikma's manufacturing facility to enable clinical manufacturing. "Thereafter, Hikma will make milestone payments of up to $75m at various stages of development, including the delivery of pharmacokinetic clinical trials, pivotal clinical trials, ANDA submissions and FDA approvals," Hikma said. "On approval, Hikma will pay a share of distributable net profit of up to a mid-teen percentage for each portfolio product. Hikma will also pay sales milestones on the achievement of certain cumulative net sales targets. Vectura will contribute up to $70 million towards Hikma's development activities for the portfolio." "Vectura's contribution to the development costs will be deferred and made through a reduced profit share mechanism following commercial launch of the first product
broadwood: Generic drugmaker Hikma Pharmaceuticals issued its interim results for the six months ended 30 June on Wednesday, reporting an 11% improvement in group revenue to $989m, or 10% in constant currency. The FTSE 250 company said its operating profit for the period was $174m, up 54%, while core group operating profit rose 22% to $214m, or 23% in constant currency. Core basic earnings per share totalled 61.4 US cents, up 35%, and 38% in constant currency, with basic earnings per share rising 53% to 44.0 cents, or 57% in constant currency. Cash flow from operations reached $185m. Hikma said its net debt fell to $501m, from $546m at the end of December, with “healthy”; leverage ratios maintained. Its board declared an interim dividend of 12 cents per share, up from 11 cents per share a year ago. The company also raised its guidance for the injectables and generics businesses, and reiterated it for the branded business. “I am pleased with our first half performance, with each of our three business segments achieving revenue and, importantly, profit growth,” said Hikma chief executive officer Siggi Olafsson. “Our injectables business continues to demonstrate resilience. “Our broad portfolio, extensive manufacturing capabilities and geographic footprint are enabling us to respond quickly to changing market dynamics and grow our market share.” Olafsson said that in the generics business, Hikma was “successfully” driving demand for its “more differentiated”; in-market products, and was making progress reducing its cost base. “We achieved good results in the branded business, taking into consideration the usual seasonality. “In the first half, we renewed our focus on advancing our pipnlinee, enhancing our corporate research and development team and accelerating new projects. “More broadly, we are strengthening key functions across the group and bringing new capabilities to ensure we have the right teams in place to take the business forward.” Hikma’s performance in the first half exceeded the board’s expectations, Olafsson said, and it was reportedly “pleased”; to be able to raise its guidance for both the injectables and generics businesses for the full year. “The measures we have taken and investments we have made across the group over the past year are delivering results, but we still have work to do. “Our markets are competitive and we don't expect the same demand for some of our injectable products to continue into 2019,” Siggi Olafsson explained. “This means we must remain focused on strengthening our customer relationships, improving profitability and advancing our pipeline to ensure future growth.”
jswjsw: RNS: "London, 30 May 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that its wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp. (West-Ward), has launched Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine(R) .(1) Methylergonovine Maleate Tablets are a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage." ----------------- Why on earth this has caused the share price to tank is just beyond me... j
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201203 07:13:40